The Second Battlefield for Solid Tumor CAR-T: A Global Race in the Intracranial Arena -- Who Is Leading?
T-MAXIMUM PHARMACEUTICAL Inc's Universal CAR-T First-in-Human Data to Debut at the World Conference on Lung Cancer BEIJING, July 21, 2026 /PRNewswire/ -- Recently, the 2026 World Conference on Lung Cancer (WCLC) released a set of abstracts that drew...
CARsgen Announced 2024 Annual Results
SHANGHAI, March 19, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced its 2024 Annual Results. Business Highlights Zevor-cel was approved by...
CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK, "CARsgen Therapeutics"), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors,...
GRIT Bio Appoints Jie Jia, Ph.D., as Chief Operating Officer
SHENZHEN, China, Jan. 3, 2025 /PRNewswire/ -- Shenzhen GRIT Biotechnology Co., Ltd., a leading company in cell therapy globally, today announced the appointment of Jie Jia, Ph.D., as Chief Operating Officer (COO), effective on the date of this press...